Tecentriq Disappoints In Post-Surgery Bladder Cancer
Fails To Hit Disease-Free Survival
Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
You may also be interested in...
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.
Dame Emma Walmsley has delivered a broadside to the UK government, urging it to reverse a raised revenues ‘clawback’ for pharma companies and boost new medicines uptake in order to maintain the UK’s competitiveness in life sciences.